Efficacy and safety of an increased-dose of dexamethasone in patients receiving fosaprepitant chemotherapy in Japan

3Citations
Citations of this article
10Readers
Mendeley users who have this article in their library.

Abstract

Background: Antiemetic triplet therapy including dexamethasone (DEX) is widely used for patients receiving highly emetogenic chemotherapy (HEC). In Japan, the appropriate dose of DEX has not been established for this combination. Materials and Methods: To assess the efficacy and safety of increased-dose DEX, we retrospectively examined patients receiving HEC with antiemetic triplet therapy. Results: Twenty-four patients (fosaprepitant group) were given an increased-dose of DEX (average total dose: 45.8mg), fosaprepitant, and 5-HT3 antagonist. A lower-dose of DEX (33.6mg), oral aprepitant, and 5-HT3 antagonist were administered to the other 48 patients (aprepitant group). The vomiting control rates in the fosaprepitant and aprepitant groups were 100% and 85.4% in the acute phase, and were 75.0% and 64.6% in the delayed phase. The incidences of toxicity were similar comparing the two groups. Conclusions: Triplet therapy using an increased-dose of DEX is suggested to be safe and effective for patients receiving HEC.

References Powered by Scopus

The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: A multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin - The Aprepitant Protocol 052 Study Group

741Citations
N/AReaders
Get full text

Guideline update for MASCC and ESMO in the prevention of chemotherapy-and radiotherapy-induced nausea and vomiting: Results of the Perugia consensus conference

614Citations
N/AReaders
Get full text

A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy

321Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Dexamethasone disrupts cytoskeleton organization and migration of T47D human breast cancer cells by modulating the AKT/mTOR/RhoA pathway

26Citations
N/AReaders
Get full text

Anticipatory nausea in animal models: A review of potential novel therapeutic treatments

16Citations
N/AReaders
Get full text

Chinese expert consensus on prevention and treatment of delayed nausea and vomiting (2022 Edition)

0Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Kumagai, H., Kusaba, H., Okumura, Y., Komoda, M., Nakano, M., Tamura, S., … Baba, E. (2014). Efficacy and safety of an increased-dose of dexamethasone in patients receiving fosaprepitant chemotherapy in Japan. Asian Pacific Journal of Cancer Prevention, 15(1), 461–465. https://doi.org/10.7314/APJCP.2014.15.1.461

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 4

50%

Researcher 2

25%

Professor / Associate Prof. 1

13%

Lecturer / Post doc 1

13%

Readers' Discipline

Tooltip

Medicine and Dentistry 4

44%

Pharmacology, Toxicology and Pharmaceut... 4

44%

Agricultural and Biological Sciences 1

11%

Save time finding and organizing research with Mendeley

Sign up for free